4//SEC Filing
Lippoldt Darin 4
Accession 0000914475-25-000050
CIK 0000914475other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 6:49 PM ET
Size
9.3 KB
Accession
0000914475-25-000050
Insider Transaction Report
Form 4
Lippoldt Darin
Chief Legal Officer
Transactions
- Exercise/Conversion
Common Stock
2025-02-08+1,727→ 42,590 total - Exercise/Conversion
Restricted Stock Unit
2025-02-08−1,727→ 0 total→ Common Stock (1,727 underlying) - Sale
Common Stock
2025-02-10$118.25/sh−911$107,727→ 41,679 total
Footnotes (4)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.07 to $123.53 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F4]This RSU was granted to the Reporting Person on February 8, 2021. In accordance with the terms of the RSU, the award vested as to 1,727 shares on February 8, 2022, vested as to 1,727 shares on February 8, 2023, vested as to 1,727 shares on February 8, 2024, and vested as to 1,727 shares on February 8, 2025, subject to the terms and conditions of the award.
Documents
Issuer
NEUROCRINE BIOSCIENCES INC
CIK 0000914475
Entity typeother
Related Parties
1- filerCIK 0001504783
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 6:49 PM ET
- Size
- 9.3 KB